ISRCTN14727552
Completed
未知
FluCare Phase 2: Estimating the effectiveness and cost-effectiveness of a complex intervention to increase care home staff influenza vaccination rates – a feasibility study
niversity of East Anglia0 sites500 target enrollmentAugust 27, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Influenza vaccination in care home staff
- Sponsor
- niversity of East Anglia
- Enrollment
- 500
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Care homes:
- •1\. Long stay for older residents or dementia registration
- •2\. Self\-reported staff vaccination rate \<40% (verified with DHSC Capacity Tracker)
- •3\. Must be signed up to the DHSC Capacity Tracker and willing to provide weekly updates on flu vaccine status of staff and residents
Exclusion Criteria
- •Care homes with fewer than 10 staff members
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosasEUCTR2010-018430-48-ESGrupo Español Multidisciplinar en cáncer Digestivo-GEMCAD
Active, not recruiting
Phase 1
A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)Huntington's diseaseMedDRA version: 18.0Level: PTClassification code 10070668Term: Huntington's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-005112-42-FRINSERM50
Completed
Phase 2
A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (HD)Huntington's Diseaseneurodegenerative movement disorder1002929910028037NL-OMON43815The French National Institute of Health and Medical Research (Inserm)50
Active, not recruiting
Phase 1
A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)Huntington's diseaseMedDRA version: 20.0Level: PTClassification code 10070668Term: Huntington's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2014-005112-42-NLINSERM100
Active, not recruiting
Phase 1
Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factorsmetastatic pancreatic carcinomaMedDRA version: 18.1Level: LLTClassification code 10033576Term: Pancreas carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-005471-17-DEKlinikum der Universität München-Großhadern150